These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 26730167)

  • 21. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
    Ozdil B; Akkiz H; Bayram S; Bekar A; Akgöllü E; Sandikçi M
    Turk J Gastroenterol; 2010 Mar; 21(1):23-8. PubMed ID: 20533108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori.
    Lin YA; Wang H; Gu ZJ; Wang WJ; Zeng XY; Du YL; Ying SS; Zhang BH
    Med Sci Monit; 2017 Jun; 23():2701-2707. PubMed ID: 28577017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
    Prasertpetmanee S; Mahachai V; Vilaichone RK
    Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection].
    Campillo A; Amorena E; Ostiz M; Kutz M; LaIglesia M
    Gastroenterol Hepatol; 2016 Nov; 39(9):584-589. PubMed ID: 27084668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
    Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
    Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with
    Lee YD; Kim SE; Park SJ; Park MI; Moon W; Kim JH; Jung K; Song J
    Korean J Gastroenterol; 2020 Sep; 76(3):142-149. PubMed ID: 32969362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects.
    Lee VW; Chau TS; Chan AK; Lee KK; Waye MM; Ling TK; Chan FK
    J Clin Pharm Ther; 2010 Jun; 35(3):343-50. PubMed ID: 20831535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
    Grgov S; Tasić T; Radovanović-Dinić B; Benedeto-Stojanov D
    Vojnosanit Pregl; 2016 Nov; 73(11):1044-9. PubMed ID: 29328644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.
    Sapone A; Vaira D; Trespidi S; Perna F; Gatta L; Tampieri A; Ricci C; Cantelli-Forti G; Miglioli M; Biagi GL; Paolini M
    Am J Gastroenterol; 2003 May; 98(5):1010-5. PubMed ID: 12809821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.
    Liou JM; Chen CC; Chen MJ; Chang CY; Fang YJ; Lee JY; Sheng WH; Wang HP; Wu MS; Lin JT
    J Antimicrob Chemother; 2011 Aug; 66(8):1847-52. PubMed ID: 21632579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.
    Miehlke S; Schneider-Brachert W; Kirsch C; Morgner A; Madisch A; Kuhlisch E; Haferland C; Bästlein E; Jebens C; Zekorn C; Knoth H; Stolte M; Lehn N
    Helicobacter; 2008 Feb; 13(1):69-74. PubMed ID: 18205669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
    Hirata Y; Serizawa T; Shichijo S; Suzuki N; Sakitani K; Hayakawa Y; Yamada A; Koike K
    Int J Infect Dis; 2016 Oct; 51():66-69. PubMed ID: 27590563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
    Prapitpaiboon H; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2015; 16(10):4353-6. PubMed ID: 26028098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastric Juice-Based Real-Time PCR for Tailored
    Peng X; Song Z; He L; Lin S; Gong Y; Sun L; Zhao F; Gu Y; You Y; Zhou L; Zhang J
    Int J Med Sci; 2017; 14(6):595-601. PubMed ID: 28638276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
    Adachi T; Matsui S; Watanabe T; Okamoto K; Okamoto A; Kono M; Yamada M; Nagai T; Komeda Y; Minaga K; Kamata K; Yamao K; Takenaka M; Asakuma Y; Sakurai T; Nishida N; Kashida H; Kudo M
    Oncology; 2017; 93 Suppl 1():15-19. PubMed ID: 29258111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
    Karaca RO; Kalkisim S; Altinbas A; Kilincalp S; Yuksel I; Goktas MT; Yasar U; Bozkurt A; Babaoglu MO
    Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):199-206. PubMed ID: 27611887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
    Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.